This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
Retail and Core Retail Sales Jump in September
by Zacks Equity Research
Retail and Core Retail Sales Jump in September.
Retail Sales +1.9%, Industrial Production -0.6%
by Mark Vickery
While September Retail Sales were ahead of expectations, Industrial Production last month was decidedly not.
Moderna Gets Consent to File MAA for Coronavirus Vaccine in EU
by Zacks Equity Research
Moderna (MRNA) gets permission from the European Medicines Agency to submit a marketing authorization application for mRNA-1273, its vaccine candidate against COVID-19.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $86.23 in the latest trading session, marking a +0.75% move from the prior day.
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Company News for Oct 7, 2020
by Zacks Equity Research
Companies in the news are: KNSA, GMDA, BNTX, NAKD
Pfizer, BioNTech Begin EU Rolling Filing of Coronavirus Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech start rolling review of their coronavirus vaccine candidate, BNT162b2, in Europe.
Small-Caps, Energy Win the Trading Day
by Mark Vickery
The Energy sector was one of the biggest winners on the day, coming after weeks of hard-hit commodity prices finally getting a little traction.
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
Moderna Coronavirus Vaccine May Not Be Ready Before US Elections
by Zacks Equity Research
Moderna (MRNA) does not expect to apply for an emergency use authorization for its mRNA-based coronavirus before the U.S. presidential election scheduled on Nov 3.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $66.86 in the latest trading session, marking a +0.54% move from the prior day.
4 Coronavirus Vaccine Makers Now in Phase III as J&J Begins Study
by Kinjel Shah
COVID-19 vaccine candidates of four companies - J&J, Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna - are now in late-stage development.
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
by Ritujay Ghosh
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $67 in the latest trading session, marking a +0.33% move from the prior day.
BioNTech Gets New Funding for Coronavirus Vaccine Development
by Zacks Equity Research
BioNTech (BNTX) receives grant of up to almost $445 million to support development and potential approval of its coronavirus vaccine candidate.
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
Pfizer Seeks to Raise Coronavirus Study Enrollment Target
by Zacks Equity Research
Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.
Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.
Pausing of AstraZeneca's Coronavirus Study Aids Pfizer, Moderna
by Indrajit Bandyopadhyay
The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.
Moderna Gets Rating Downgrade, Takes Safety Pledge, Stock Down
by Zacks Equity Research
Moderna (MRNA) pledges with eight other pharma companies to ensure commercialization of a safe and effective vaccine. However, anticipated competitive pressure weighs on the stock.
CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge
by Kinjel Shah
The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).